Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.2828
+0.0054 (1.95%)
At close: Jul 17, 2026, 4:00 PM EDT
0.2716
-0.0112 (-3.96%)
After-hours: Jul 17, 2026, 6:12 PM EDT
Ensysce Biosciences Employees
As of December 31, 2025, Ensysce Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$470,788
Profits / Employee
-$1,178,654
Market Cap
4.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 2 | 25.00% | 8 | 2 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| PMGC Holdings | 34 |
| FibroBiologics | 15 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
ENSC News
- 4 days ago - Ensysce Biosciences awarded $5.3M installment in NIDA funding - TheFly
- 4 days ago - Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Accesswire
- 22 days ago - Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 - TheFly
- 22 days ago - Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 6 weeks ago - Ensysce Biosciences files to sell 1.3M shares of common stock for holders - TheFly
- 6 weeks ago - Ensysce Biosciences Registration statement: Registration filing - Filings
- 2 months ago - Ensysce Biosciences Reports First Quarter 2026 Financial Results - Accesswire
- 2 months ago - Ensysce Biosciences Quarterly report: Q1 2026 - Filings